Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 3/2012

01-06-2012 | Original Article

Relationship between serum cystatin C and serum adiponectin level in type 2 diabetic patients

Authors: Yoshiya Hosokawa, Yuya Yamada, Yoshinari Obata, Megu Yamaguchi Baden, Kenji Saisho, Arisa Ihara, Koji Yamamoto, Kiyonori Katsuragi, Yuji Matsuzawa

Published in: Clinical and Experimental Nephrology | Issue 3/2012

Login to get access

Abstract

Background

To investigate the relationship between serum levels of cystatin C and adiponectin in patients with type 2 diabetes.

Methods

We examined serum cystatin C and adiponectin levels in 234 patients with type 2 diabetes who visited our hospital.

Results

The serum level of cystatin C was positively correlated with age (P < 0.001), duration of diabetes (P = 0.013), serum creatinine (P < 0.001), uric acid (P < 0.001), and adiponectin (p = 0.001), while it was inversely correlated with estimated glomerular filtration rate (P < 0.001). Serum adiponectin was significantly higher in patients with high serum cystatin C levels than in those with normal cystatin C levels (8.3 ± 4.7 and 6.2 ± 3.2 μg/mL, respectively; P < 0.001). Adiponectin was also significantly higher in male patients with high cystatin C levels, but not in females. In multiple regression analysis, serum adiponectin was also independently and significantly correlated to age, diastolic blood pressure, high-density lipoprotein cholesterol, triglyceride and serum cystatin C.

Conclusions

Serum adiponectin level was correlated with serum cystatin C level on simple and multiple regression analyses in patients with type 2 diabetes. Although circulating adiponectin is increased in advanced kidney disease, it might be biologically inactive due to binding to cystatin C and thus not display an anti-arteriosclerotic effect.
Literature
1.
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 2009;257:79–83.CrossRef
2.
Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51:1884–8.PubMedCrossRef
3.
Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Curr Pharm Des. 2010;16:1896–901.PubMedCrossRef
4.
Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360:57–8.PubMedCrossRef
5.
Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85–9.PubMedCrossRef
6.
Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–7.PubMedCrossRef
7.
Fujita H, Morii T, Koshimura J, Ishikawa M, Kato M, Miura T, et al. Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy. Endocr J. 2006;53:745–52.PubMedCrossRef
8.
George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart. 2006;92:1420–4.PubMedCrossRef
9.
Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, Nishizawa H, et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care. 2002;25:1665.PubMedCrossRef
10.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.CrossRef
11.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.PubMedCrossRef
12.
Krolewski AS, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med. 1987;317:1390–8.PubMedCrossRef
13.
Masaie H, Oritani K, Yokota T, Takahashi I, Shirogane T, Ujiie H, et al. Adiponectin binds to chemokines via the globular head and modulates interactions between chemokines and heparan sulfates. Exp Hematol. 2007;35:947–56.PubMedCrossRef
14.
Komura N, Kihara S, Sonoda M, Maeda N, Tochino Y, Funahashi T, et al. Increment and impairment of adiponectin in renal failure. Cardiovasc Res. 2010;86:471–7.PubMedCrossRef
15.
Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–6.PubMedCrossRef
16.
Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049–60.PubMedCrossRef
17.
Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115:173–9.PubMedCrossRef
18.
The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc. 2010;53:450–67 (article in Japanese).
19.
Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol. 2009;13:537–66.CrossRef
20.
Tanaka M, Matsuo K, Enomoto M, Mizuno K. A sol particle homogeneous immunoassay for measuring serum cystatin C. Clin Biochem. 2004;37:27–35.PubMedCrossRef
21.
Nishimura A, Sawai T. Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer. Clin Chim Acta. 2006;371:163–8.PubMedCrossRef
22.
Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106:2767–70.PubMedCrossRef
23.
Baden MY, Obata Y, Hosakawa Y, Saisho K, Tamba S, Yamamoto K, et al. Effects of alcohol drinking and smoking habit on serum adiponectin level in both diabetic and non-diabetic subjects. J Metab Syndr (in press) (article in Japanese).
24.
Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118:1645–56.PubMed
25.
Tsioufis C, Dimitriadis K, Chatzis D, Vasiliadou C, Tousoulis D, Papademetriou V, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol. 2005;96:946–51.PubMedCrossRef
26.
von Eynatten M, Liu D, Hock C, Oikonomou D, Baumann M, Allolio B, et al. Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes. 2009;58:2093–9.CrossRef
27.
Tsuda S, Nakano S, Konishi K, Koya D. A lack of increase in high molecular weight-adiponectin in macroalbuminuric subjects with metabolic syndrome may exert renal and atherosclerotic risks. Diabetes Res Clin Pract. 2008;79:503–9.PubMedCrossRef
28.
Kato K, Osawa H, Ochi M, Kusunoki Y, Ebisui O, Ohno K, et al. Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy. Clin Endocrinol (Oxf). 2008;68:442–9.
29.
Krizer JR, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrinol Metab. 2008;93:3357–64.CrossRef
Metadata
Title
Relationship between serum cystatin C and serum adiponectin level in type 2 diabetic patients
Authors
Yoshiya Hosokawa
Yuya Yamada
Yoshinari Obata
Megu Yamaguchi Baden
Kenji Saisho
Arisa Ihara
Koji Yamamoto
Kiyonori Katsuragi
Yuji Matsuzawa
Publication date
01-06-2012
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2012
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0571-5

Other articles of this Issue 3/2012

Clinical and Experimental Nephrology 3/2012 Go to the issue

Case Report

Severe intraglomerular detachment of podocytes in a Gitelman syndrome patient

Original Article

Home systolic blood pressure on the morning of dialysis days has prognostic impact for hypertensive hemodialysis patients

Original Article

Characteristics of spontaneous calcium oscillations in renal tubular epithelial cells

Original Article

Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis

Case Report

Diffuse tubulointerstitial nephritis associated with ANCA-negative pauci-immune glomerulonephritis

Original Article

The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits